HHHasan Hamam

Hasan Hamam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hasan Hamam has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extensive Iliofemoral Deep Vein Thrombosis Secondary to Uterine Leiomyoma-Induced Iliac Vein Compression: A Case Report

    by Noor Albaraq, Hasan J Hamam

    Deep vein thrombosis (DVT) is an acute vascular condition commonly associated with immobility, hypercoagulability, and endothelial injury. We report the case of a 47-year-old woman presenting with progressive left lower extremity swelling and pain, ultimately diagnosed with extensive iliofemoral DVT secondary to extrinsic compression of the left common iliac vein by a markedly enlarged fibroid uterus. The patient was managed with therapeutic anticoagulation, blood transfusion, and intravenous iron therapy, followed by definitive hysterectomy approximately two months later, with guideline-directed perioperative apixaban interruption and resumption without bridging anticoagulation. This case highlights the importance of cross-sectional imaging in identifying pelvic mass effect as an underrecognized cause of extensive unilateral DVT and the need for definitive treatment of the underlying compressive pathology.

  • Open Access

    Comparative Proteomic Analysis of Self‐Compatible Turnera Mutants Suggests Glutathione S‐Transferase 8 Is Involved in Overcoming S‐Morph Female Self‐Incompatibility Response

    by Paige M. Henning, Paul D. J. Chafe, Hasan J. Hamam, Joel S. Shore

    Distyly is a reproductive system, characterized by the presence of two floral morphs, which promotes outcrossing via physical and biochemical means. In distylous Turnera , the mating type of the S‐morph is determined by two genes: YUC6 (male) and BAHD (female). Despite the importance of these S ‐genes, it is likely that additional genes are involved in the distylous syndrome. Here, we use comparative mass spectrometry analysis to identify differentially expressed proteins in a series of self‐compatible mutants and wildtype distylous members of Turnera . Our analysis identified a member of the Glutathione S‐transferase family that overwhelmingly correlated with L‐morph male mating type. Exploration of the large datasets and previously published work led to the proposal that differential ROS levels in the pistil may contribute towards the self‐incompatibility response. To support this hypothesis, we generated a co‐expression network for whole flower buds from self‐compatible and WT Turnera joelii . This network led to the identification of a series of ROS and auxin‐related genes that correlated with self‐compatibility. We update previously proposed SI response models to reflect how ROS, jasmonic acid, and brassinosteroid signaling likely establish the S‐morph female self‐incompatibility response. Overall, this work has identified genes potentially related to self‐compatibility and has provided a foundation for future empirical work investigating the basis of the SI response in Turnera .

  • Open Access

    Impact of concomitant corticosteroid use on adverse events in ulcerative colitis clinical trials

    by Hasan Hamam, Parambir S Dulai, John K Marshall, Christopher Ma, Vipul Jairath, Walter Reinisch, Neeraj Narula

    Background and Aims: Adverse events (AEs) are frequently reported in clinical trials of advanced therapies for ulcerative colitis (UC). It remains uncertain whether patients receiving concomitant corticosteroids experience higher AE rates. This study aimed to determine whether corticosteroid use is associated with increased AEs in UC trials. Methods: This post-hoc analysis used participant-level data from several placebo-controlled trials (GEMINI-1, ULTRA-2, VARSITY, ACT-1, OCTAVE, and PURSUIT). The primary population included induction responders with or without baseline corticosteroid use. The primary outcome assessed the association between corticosteroid use and total AEs. Secondary outcomes included AE rates among those who achieved corticosteroid-free remission versus those who did not, and whether specific AEs were more common in corticosteroid users. Results: Among 2339 patients who achieved clinical response after induction, 1159 (49.5%) used corticosteroids at baseline. By 1 year, AE incidence was higher among corticosteroid users than non-users (75.2% vs. 67.6%, P < .001). Patients who achieved corticosteroid-free remission had fewer AEs than those who did not (67.4% vs. 77.5%, P < .001). Moderate AEs were more frequent among corticosteroid users. Common AEs included infections (in both groups) and liver abnormalities (more in corticosteroid users). Multivariable logistic regression confirmed baseline corticosteroid use as an independent AE risk factor [odds ratio (OR) 1.5, 95% CI 1.3–1.8, P = .002]. Ongoing corticosteroid use at 1 year was associated with even higher AE risk (OR 4.6, 95% CI 2.1–6.8, P < .001). Conclusion: Corticosteroid use is independently associated with increased AEs in UC clinical trials. Continued monitoring and strategies for corticosteroid tapering may reduce AE burden.


  • Open Access

    Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)

    by Neeraj Narula, Cara Pray, Hasan Hamam, Farhad Peerani, Tawnya Hansen, Talat Bessissow, Brian Bressler, Arathi Arun, Maria Schmit, Jane Castelli, et al.

    Background: Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with increasing evidence of effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there are scarce prospective data analyzing the efficacy and rapidity of action in hospitalized ASUC. Methods: The TRIUMPH study is a prospective open-label interventional trial of tofacitinib in hospitalized patients with ASUC conducted in 5 hospitals across Canada (Clinicaltrials.gov: NCT04925973). Eligible participants included biologic-naïve and experienced patients with ASUC refractory to 3 days of intravenous (IV) corticosteroids (Modified Truelove-Witts Severity Index [MTWSI] > 10 despite steroids). Participants were treated with tofacitinib 10 mg twice daily and assessed daily while in hospital. The primary outcome was day 7 clinical response (MTWSI reduction of > 3 from baseline and ≤ 10). Results: Among 24 subjects, 33.3% (8/24) had previous anti-TNF failure. Day 7 clinical response was achieved in 58.3% (14/24). The mean number of days to achieve clinical response was 2.4 (SD 1.3). Marked reduction in C-reactive protein was observed in responders within the first two days after tofacitinib initiation compared to nonresponders. Colectomy occurred in 25% (6/24) by 6 months, with no additional colectomy beyond this time point. Five participants reported a total of 13 adverse events. Conclusions: Tofacitinib is an effective rescue therapy in hospitalized patients with steroid-refractory ASUC. Randomized controlled trials are warranted to compare JAK inhibitors with other rescue therapies, including infliximab in steroid-refractory ASUC (Clinicaltrials.gov: NCT04925973).


  • Open Access

    Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel Disease

    by Sunil Samnani, Emily C L Wong, Hasan Hamam, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

    Background and Aims: Inflammatory bowel disease (IBD) trials often stratify patients by prior biologic exposure, including prior biologic failure or intolerance. This study aimed to assess clinical outcomes in IBD patients with prior biologic failure vs intolerance treated with ustekinumab or vedolizumab. Methods: A post-hoc analysis of ulcerative colitis (UC) and Crohn’s disease (CD) clinical trials for ustekinumab (UNITI and UNIFI) and vedolizumab (GEMINI-1 and GEMINI-2) was performed. Clinical response, clinical remission, and endoscopic improvement (for UC) were compared among biologic naïve, biologic failure, and biologic intolerant patients. Statistical analyses, including chi-square tests and logistic regression, were performed. Results: A total of 1178 UC and 1439 CD patients received either ustekinumab or vedolizumab. In UC, biologic intolerant patients exhibited higher clinical response (54.7% vs 38.8%, aOR 1.87 [95% CI, 0.93-3.73]), clinical remission (25.0% vs 11.0%, aOR 2.84 [95% CI, 1.47-5.49]), and endoscopic improvement (40.6% vs 24.8%, aOR 2.76 [95% CI, 1.28-5.94]) compared to biologic failure, with outcomes similar to biologic naïve patients. In biologic intolerant CD patients, clinical response was similar between prior biologic failure and intolerance (34.2% vs 32.8%), but after adjustment for potential confounders, biologic intolerance was associated with higher odds of clinical response (aOR: 1.67, 95% CI, 1.09-2.55), with no significant difference observed for clinical remission (aOR: 1.48, 95% CI, 0.88-2.49). Conclusions: Improved treatment outcomes were generally observed in patients with biologic intolerance compared to failure, especially in UC, where outcomes were similar to biologic naïve patients. Future clinical trials should meticulously differentiate prior biologic failure vs intolerance to mitigate potential bias.


  • Resolution of Rectal Bleeding by Day 7 in Acute Severe Ulcerative Colitis Is Prognostic for Postdischarge Corticosteroid-Free Clinical Remission and Endoscopic Improvement

    by Neeraj Narula, Hasan Hamam, Farhad Peerani, Talat Bessissow, Brian Bressler, Parambir S. Dulai

    This study assesses 2 different disease activity measures, the Modified Truelove Witts Severity Index and the partial Mayo score, in hospitalized patients with acute severe ulcerative colitis (UC) for prediction of postdischarge corticosteroid-free clinical remission and endoscopic improvement to help guide future considerations for disease activity assessment. In this post hoc analysis from the Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (TRIUMPH) trial, these results suggest resolution of the Mayo rectal bleeding subscore may have high prognostic utility and could be considered as a primary end point for hospitalized UC trials. The study underscores the need for further research on patient-reported outcomes and endoscopic indices in larger populations for inpatient UC trials.


  • Open Access

    Pistil Mating Type and Morphology Are Mediated by the Brassinosteroid Inactivating Activity of the S-Locus Gene BAHD in Heterostylous Turnera Species

    by Courtney M. Matzke, Hasan J. Hamam, Paige M. Henning, Kyra Dougherty, Joel S. Shore, Michael M. Neff, Andrew G. McCubbin

    Heterostyly is a breeding system that promotes outbreeding through a combination of morphological and physiological floral traits. In Turnera these traits are governed by a single, hemizygous S-locus containing just three genes. We report that the S-locus gene, BAHD, is mutated and encodes a severely truncated protein in a self-compatible long homostyle species. Further, a self-compatible long homostyle mutant possesses a T. krapovickasii BAHD allele with a point mutation in a highly conserved domain of BAHD acyl transferases. Wild type and mutant TkBAHD alleles were expressed in Arabidopsis to assay for brassinosteroid (BR) inactivating activity. The wild type but not mutant allele caused dwarfism, consistent with the wild type possessing, but the mutant allele having lost, BR inactivating activity. To investigate whether BRs act directly in self-incompatibility, BRs were added to in vitro pollen cultures of the two mating types. A small morph specific stimulatory effect on pollen tube growth was found with 5 µM brassinolide, but no genotype specific inhibition was observed. These results suggest that BAHD acts pleiotropically to mediate pistil length and physiological mating type through BR inactivation, and that in regard to self-incompatibility, BR acts by differentially regulating gene expression in pistils, rather than directly on pollen.